More Access and Evidence Articles

Access and Evidence

Value: A Balancing Act

Ross Davies, (Oct 16, 2018)

When it comes to proving the value of a new medicine, pharma has to strike the right balance
Access and Evidence

Can Payers Trust Our Data?

Andrew Stone, (Oct 16, 2018)

Analyses from RWD are playing an increasingly important role, but will payers accept pharma’s figures?
Access and Evidence

Diving for Data

Andrew Stone, (Oct 16, 2018)

Finding the right data to underpin outcome-based contracts is not as easy as it looks
Access and Evidence

Rid Yourself Of Dirty Data

Andrew Stone, (Oct 11, 2018)

Real-world data holds enormous potential. But it also risks being riddled with bias.
Access and Evidence

Could Digital Medicines Improve Access For All?

Danielle Barron, (Sep 4, 2018)

Digital medicines could provide a new roadmap to reimbursement and regulatory approval.
Access and Evidence

Talking The Same Language

Adam Chapman, (Aug 10, 2018)

A universal standard for real-world evidence no longer seems quixotic. But how are companies going to do it?
Access and Evidence

Going Through the Motions

Adam Chapman, (Aug 6, 2018)

Both pharma and payers say they need to talk more, but are they really listening?
Access and Evidence

Navigating the Chaos

Adam Chapman, (Aug 6, 2018)

With the access landscape shifting rapidly, pharma needs to watch its step
Access and Evidence

Seeking the Holy Grail of RWE

Adam Chapman, (Aug 2, 2018)

Universal standards for real-world evidence are closer than you might think
Access and Evidence

United: How employers are changing healthcare

Hugh Gosling, (Jul 27, 2018)

The growth in employer coalitions are a sign that plan sponsors are increasingly flexing their muscles, but what do they hope to achieve?

Pages